INKT
MiNK Therapeutics, Inc.
There isn't enough reported data to score INKT yet.
INKT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
INKT's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
INKT PE Valuation
INKT has no meaningful PE right now: it lost money over the past year.
INKT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect INKT's losses to grow, with revenue growing.
INKT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.21 | +$0.76 |
| Q2 2026 | -$2.36 | +$0.46 |
| Q1 2026 | -$2.80 | -$0.34 |
| Q4 2025 | -$2.93 | -$0.07 |
| Q3 2025 | -$2.97 | +$0.83 |
| Q2 2025 | -$2.82 | +$1.98 |
| Q1 2025 | -$2.46 | +$3.44 |
| Q4 2024 | -$2.86 | +$3.64 |
INKT is still losing money, but far less than before: $2.21 per share over the past year, against $10.04 at its worst in late 2021.
INKT Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1319% | N/A |
INKT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.1M | -$513.6K |
| Q1 2026 | -$1.7M | -$391.7K |
| Q4 2023 | -$3M | +$1.5M |
| Q3 2023 | -$4.2M | +$1.4M |
| Q4 2022 | -$4.6M | -$2.9M |
| Q4 2021 | -$1.7M | +$15.7K |
| Q2 2021 | -$3.5M | -$1.5M |
| Q1 2021 | -$4.2M | -$2.2M |
INKT has burned cash in almost every quarter: −$7M over the past year, against −$10M the year before.
INKT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.6% | +79.2K shares |
| 1 year | +15% | +659K shares |
| 3 years | +48% | +1.7M shares |
| 5 years | +80% | +2.3M shares |
| Available history | +112% | +2.7M shares |
INKT has 5M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
INKT Net Leverage
INKT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
INKT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.9 | Neutral |
| Stochastic | 25.0 | Neutral |
INKT's weekly RSI is 41 (neutral) and its Stochastic is 25 (neutral).
INKT PE vs Healthcare Sector
INKT has no meaningful PE right now: it lost money over the past year.
INKT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.7 | 11% below |
| 20 week MA | $11.1 | 14% below |
| 50 week MA | $11.3 | 16% below |
| 100 week MA | $11.5 | 17% below |
| 200 week MA | $12.1 | 21% below |
INKT is in a downtrend: it's below all five of its weekly moving averages, and 21% below its 200-week average.
INKT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $120.0 | $46.8 | -61% |
| 2022 | $46.8 | $23.2 | -50% |
| 2023 | $23.2 | $10.7 | -54% |
| 2024 | $10.7 | $5.75 | -46% |
| 2025 | $5.75 | $12.0 | +108% |
| 2026 YTD | $12.0 | $9.53 | -20% |
INKT's yearly returns have swung widely, from +108% in 2025 to −61% in 2021. It's down 20% so far in 2026.